A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
606actual
Sites
207
Countries
Argentina, Australia, Austria +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-10 | actual | When the study began enrolling |
| Primary completion | 2026-07-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-25 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Multiple Myeloma
Interventions
- Drug: Mezigdomide — also filed as BMS-986348, CC-92480
- Drug: Carfilzomib — also filed as Kyprolis
- Drug: Dexamethasone — also filed as Decadron, Dex
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS)
measured Up to approximately 5 years
Publications
- PMID 42289183 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed